C-type natriuretic peptide: A new cardiac mediator |
| |
| Institution: | 1. Section of Electrophysiology, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA;2. Kidney Research Institute, University of Washington, Seattle, WA;3. Division of Nephrology, University of Washington, Seattle, WA;4. Division of Cardiology, University of Washington, Seattle, WA;5. Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Boston, MA;6. Division of Renal Diseases and Hypertension, University of Colorado Denver Health Sciences Center, Aurora, CO;7. Division of Nephrology, Tufts Medical Center, Boston, MA;8. Cardiovascular Health Research Unit, University of Washington, Seattle, WA;9. Department of Medicine, University of Washington, Seattle, WA;10. Department of Epidemiology, University of Washington, Seattle, WA;11. Department of Health Services, University of Washington, Seattle, WA;12. Center for Health Studies, Group Health, Seattle, WA;13. General Internal Medicine Section, Veterans Affairs Medical Center, San Francisco, CA;14. Department of Medicine, University of California, San Francisco, CA;15. Department of Epidemiology, University of California, San Francisco, CA;16. Department of Biostatistics, University of California, San Francisco, CA;17. Nephrology Section, Veterans Affairs San Diego Healthcare System, San Diego, San Diego, CA;18. Division of Nephrology and Preventive Medicine, University of California, San Diego, San Diego, CA;1. Division of Cardiovascular Disease, University of Kentucky, Lexington, KY 40507, USA;1. Department of General Surgery and Liver Transplantation, Croix-Rousse University Hospital, Hospices Civils de Lyon, 103 Grande Rue de la Croix-Rousse, 69317 Cedex 04, Lyon, France;2. Equipe Mixte de Recherche 3738, Ecole Doctorale EDISS 205, Université Claude Bernard Lyon 1, Villeurbanne, France;3. Ecole de Chirurgie de Lyon, Université Claude Bernard Lyon 1, Lyon, France;4. Intensive Care Unit, Croix-Rousse University Hospital, Hospices Civils de Lyon, Lyon, France;1. Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People''s Hospital, Shanghai 200233, China;2. Shanghai Clinical Center for Diabetes, Shanghai 200233, China;3. Shanghai Key Clinical Center for Metabolic Disease, Shanghai 200233, China;4. Shanghai Diabetes Institute, Shanghai 200233, China;5. Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China;1. Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China;2. Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China;3. Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University and Institute of Chronic Metabolic Diseases of Fudan University, Shanghai, China;1. Department of Biomedical Sciences, University of Copenhagen, Denmark;2. Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Canada |
| |
| Abstract: | Natriuretic peptides are endogenous hormones released by the heart in response to myocardial stretch and overload. While atrial and brain natriuretic peptides (ANP, BNP) were immediately considered cardiac hormones and their role was well-characterized and defined in predicting risk in cardiovascular disease, evidence indicating the role of C-type natriuretic peptide (CNP) in cardiovascular regulation was slow to emerge until about 8 years ago. Since then, considerable literature on CNP and the cardiovascular system has been published; the aim of this review is to examine current literature relating to CNP and cardiovascular disease, in particular its role in heart failure (HF) and myocardial infarction (MI). This review retraces the fundamental steps in research that led understanding the role of CNP in HF and MI; from increased CNP mRNA expression and plasmatic concentrations in humans and in animal models, to detection of CNP expression in cardiomyocytes, to its evaluation in human leukocytes. The traditional view of CNP as an endothelial peptide has been surpassed by the results of many studies published in recent years, and while its physiological role is still under investigation, information is now available regarding its contribution to cardiovascular function. Taken together, these observations suggest that CNP and its specific receptor, NPR-B, can play a very important role in regulating cardiac hypertrophy and remodeling, indicating NPR-B as a new potential drug target for the treatment of cardiovascular disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
